| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Arthrobacter nivea KCC B35, isolated from densely packed blue-green cushions on oil deposits along the Arabian Gulf coast, exhibits excellent growth using C10 to C40 n-alkanes as its sole carbon and energy source. Its growth on C20 to C40 alkanes is even superior to that on C10 to C18 alkanes. After co-culturing biomass samples with n-octacosane (C28) or n-nonacosane (C29) for 6 hours, these compounds became the major constituent alkanes of the cell's hydrocarbon composition. Even-chain hexadecane (C16) and odd-chain pentadecane (C15) were the second-largest constituent alkanes in C28 and C29 cultured cells, respectively. Cells incubated with n-hexadecane accumulated a higher proportion of C16 fatty acids in their lipids compared to control cells not incubated with hydrocarbon compounds. On the other hand, no fatty acids with the same chain length were detected in cells incubated with C28 and C29, but the fatty acid profile of the cellular lipids indicated that these ultra-long-chain alkanes may have undergone medium-chain oxidation. This activity makes Tobacco Monotylaceae KCC B35 suitable for use in formulations for the bioremediation of heavy oil sediment-contaminated environments. Liver, heart, kidney, muscle, and adipose tissue (perilenaciole and subcutaneous) were collected from six cattle for hydrocarbon composition analysis. Qualitative and quantitative analyses were performed using gas chromatography and gas chromatography-mass spectrometry. Although the proportions varied, a range of n-alkanes with carbon chain lengths ranging from n-C12 to n-C31 were found in all samples. Isoprene hydrocarbons, phytane and phyene (phytane-1-ene and phyten-2-ene), were also identified. (These findings are relevant to human health from consuming meat contaminated with hydrocarbons.) /n-Alkanes/ Metabolism/Metabolites Bacterium tobaccoii KCC B35, isolated from densely packed blue-green cushions on oil deposits along the Arabian Gulf coast, grew well with C10 to C40 n-alkanes as the sole carbon and energy source. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. After culturing biomass samples with n-octacosane (C28) or n-nonacosane (C29) for 6 hours, these compounds accumulated to become the major constituent alkanes of the cellular hydrocarbon composition. In cells cultured with C28 and C29, even-chain hexadecane (C16) and odd-chain pentadecane (C15) were the second largest constituent alkanes, respectively. Cells cultured with n-hexadecane accumulated a higher proportion of C16 fatty acids in their lipids compared to control cells not cultured with hydrocarbon compounds. On the other hand, no fatty acids with the same chain length were detected in C28 and C29 cultured cells, but the fatty acid profiles of the cellular lipids indicated that these ultra-long-chain alkanes may have undergone medium-chain oxidation. This activity makes the Tobacco Monotylaceae KCC B35 suitable for use in formulations for the bioremediation of heavy oil deposit-contaminated environments. |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
Identification and Uses: Docosane is a solid n-alkane containing 22 carbon atoms (C22). Solid n-alkane (paraffin) has a wide range of uses: it can be used as a cracking feedstock in gasoline blending and in oxidation and chlorination reactions. Human Exposure and Toxicity: No relevant data are currently available. Animal Studies: A series of homologous n-alkanes with carbon chain lengths ranging from n-C12 to n-C31 were found in all bovine tissue samples. Interactions After topical application of hexadecane-1-C-14 to guinea pig skin for 48 hours, the C-14 content in the epidermis, dermis, subcutaneous muscle, and some other tissues was determined. This study also measured the effect of simultaneous application of USP-grade heavy mineral oil, n-docosane and heptane, and hexadecane pretreatment on the penetration of 1-C-14 hexadecane. The results showed a higher C-14 content in the epidermis, while the accumulation in the dermis and subcutaneous tissues was relatively low. Each carrier reduced C-14 levels in the epidermis; however, docosane and mineral oil (but not heptane) reduced C-14 levels in the dermis and subcutaneous muscle. This is consistent with the fact that heavy mineral oil and docosane (but not heptane) reduced the skin toxicity of hexadecane. Pretreatment of the skin with hexadecane 48 hours before application of 1-C-14 actually increased C-14 levels in the epidermis. However, pretreatment with mineral oil:hexadecane reduced hexadecane-14 levels in both the epidermis and dermis during subsequent application of mineral oil:hexadecane-1-C-14. These results support the idea that heavy mineral oils and alkanes with carbon chains longer than 20 carbon atoms can reduce the skin toxicity of hexadecane by interfering with its penetration to the site of action. This site of action appears to be the deep epidermis or dermis. The increased epidermal absorption of hexadecane-C-14 after hexadecane pretreatment may explain why multiple applications of the same dose of hexadecane produce more severe reactions than a single application. |
| References |
|
| Additional Infomation |
Docosane is a solid, insoluble in water. It is used in organic synthesis, calibration, and temperature sensing devices. Docosane is a straight-chain alkane containing 22 carbon atoms and is a plant metabolite. It has been reported to be found in Vanilla madagascariensis, Magnolia officinalis, and other organisms with relevant data. See also: Moringa leaf oil (partial).
|
| Molecular Formula |
C22H46
|
|---|---|
| Molecular Weight |
310.60
|
| Exact Mass |
310.36
|
| CAS # |
629-97-0
|
| Related CAS # |
Docosane-d46; 260411-88-9
|
| PubChem CID |
12405
|
| Appearance |
White to off-white solid
|
| Density |
0.778 g/mL at 25 °C(lit.)
|
| Boiling Point |
369 °C(lit.)
|
| Melting Point |
42-45 °C(lit.)
|
| Flash Point |
>230 °F
|
| Vapour Pressure |
<1 mm Hg ( 21.1 °C)
|
| Index of Refraction |
1.4455
|
| LogP |
8.828
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
22
|
| Complexity |
153
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([H])([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
HOWGUJZVBDQJKV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H46/c1-3-5-7-9-11-13-15-17-19-21-22-20-18-16-14-12-10-8-6-4-2/h3-22H2,1-2H3
|
| Chemical Name |
docosane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 16.67 mg/mL (53.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2196 mL | 16.0979 mL | 32.1958 mL | |
| 5 mM | 0.6439 mL | 3.2196 mL | 6.4392 mL | |
| 10 mM | 0.3220 mL | 1.6098 mL | 3.2196 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.